Test 2-2 Flashcards
tumor types:
- carcinomas: epithelial cells - most common
- sarcomas: muscle cells ,aft cells or fibroblasts
- lymphomas: solid tumors of lymphoi tissues
- leukemias: lymphocytes and other hematopoietic cells
benign tumor growth is
- slow relatively
- somewaht differentiated cells
- usually encapsulated - doesnt spread
- not fatal unless at critical site (heart or brain)
malignant tumor growth is
- undifferentited cells
- readily metastesize
- usually fatal if untreated
tumor specific antigens (TSA)
- unique to a particular tumor and not present on normal cel types!! good to find cancer cells
- arise as a result of point mutations or gene rearrangements
- immune response targets –> may be altered self proteins
- not commonly seen in human tumors
tumor associated antigens (TAA)
- antigens shared by different tumors - also found on normal tissues EX oncofetal antigens- found on fetal butnot adult tissues
- alpha fetal protein (AFP)
- carcinoembryonic antigen (CEA)
- not therapeutic targets! ONLY detection and monitoring
AFP - alpha fetal protein
- produced by certain liver cancers AND NORMAL TISSUES
- ONLY detection and monitoring
CEA - carcinoembryonic antigen
- increases in colon cancer and smokers AND NORMAL TISSUES
- ONLY detection and monitoring
oncogenic viral antigens
Some RNA/DNA viruses that produce tumors and viral antigens on class I MHC
- EBV (DNA VIRUS) - causes B-cell lymphomas, HPV = cervical carcinoma, HBV = hepatocellular carcinoma
- HTLV-1 (RNA VIRUS) - causes adult t-cell leukemia/lymphoma (CD4t-cells)
- Tumors are relatively immunologenic bc seen as foreign
differentiation antigens
- tissue specific antigens
- aid in diagnosing certain tumosr = reveal the tissue of origin
- EX) pre b-cell tumors express CD10: T-cell leukemias express CD4, CD8, TCR, or IL2 receptor
antibody for anti-tumor immunity
LEAST EFFECTIVE METHOD
- difficult for immune system to respond to tumors bc 1) rarely inflammation (dont elicit co-stim molecules) 2) many tumors dont express unique antigenic peptides
- antibodies stimulated by tumor antigens DONT inhibit tumor growth
- some killing of tumor cells via ADCC by NK or macrophages
CTLs for anti-tumor immunity
produced against carcinomas, sarcomas, and virus induced tumors
- most effective against virus induced tumors
- tumor infiltrating lymphocytes (TILs) in solid tumors largely composed of anti-tumor CTLs –> for some reason they dont do anything
- SEE peptides on class I MHC
NK cells for anti-tumor immunity
- lyse tumors of hematopoietic and virus induced origins
- ADCC may be important also in some tumors
- activating signal = downreg of class I MHC
- interferons- TNF-alpha and IL2 enhance NK cells lysis of tumor cells
- lymphokine activated killer cells (LAK) - enhanced killing of various tumor cell types as well as broadened tumor recognition cpability (malignant melanomas)
macrophages for anti-tumor immunity
- kill tumor cells by ADCC or by release of TNF-alpha
- TNF-alpha (TUMOR NECROSIS FACTOR) can directly lyse tumor cells possibly by producing free radicals or by causing hemorrhagic necrosis of the tumor blood vessels
tumor evasion strategies
- lack of expression MHC proteins
- MHC proteins cant bind tumor antigen - no antigen presentation
- induce tolerance –> no costimulatory molecules
- sneaking through - small numbers of tumor cells may not be immunogenic = by the time they reach immunogenic numbers mutation have occurred to change antigen specificity
- selection of poorly immunogenic variants-
- tumor cells may grow so fast to outdistance immune response-
- anti-tumor antibodies may act as blocking factors-antibodies that bind tumor cells and immune sysmte then cant see those tumor cells
- antigens shed by tumor cells may bind to cell surface receptors - antibodies bind and tumor sheds those proteins or cuts antibodies off
- modulation of tumor antigens masked by mucopolysaccharides
- immunosuppressive substances released by tumor ex)TGF-beta
- immunoproviledged sie by encasing themselves in collagen and fibrin
selection of poorly immunogenic variants-
difficult to make immune resp against tumor cells - when a tumor cells proliferate and mutate rapidly… the immunogenic tumor cells ARE FOUND AND DESTROYED by the immune system. By the time you diagnose the cancer you only have the poorly immunogenic left which are hard to kill!
tumor treatments - nonimmunogenic
- surgery - reduce tumor load;remove before metastesizes;uses drugs in combo with surgery
- hyperthermia-destroy tumor cells throuw superheating of body tissues
- ***radiotherapy- x-rays or cobal 60 =ionizing radiation = destroys rapidly dividing cells; works best on welldefined nonmetastasized tumors;sideeffects=damage to bone marrow and intestinal mucosa;inc susceptibility to infection (destruction of radiosensitive lymphocytes);may induce 2ndary tumor formation because of induce DNA mutations
- ***chemo-inhibits DNA rep RNA transcription, or protein synth;side effects=immunosuppression can be life threatening& may induce secondary tumors
tumor immunotherapy advantages:
- specifically tailor a response to the tumor
- fewer side effects that nonspecific therapies
- more effective against tumor metastisis
tumor vaccines
vaccinate with tumor cells treated to inc immunogenicity or dendritic cells that have been loaded with tumor antigens
- melanoma (MAGE) antigens used in clinical studies to induce CTLs
- HEP B vaccine has decreased incidence of hepatocellular carcinoma
Antibody therapies
1) anti-id antibodies surface immunoglobulin of Bcell lymphomas
2) antibodies directed against growth factor receptors
3) immunoconjugates
4) bi-specific antibodies
5) purging bone marrow of tumor cells
6) adoptive cellular immunotherapy -lymphokine activated cell therapy and umor infiltrating lymphocytes therapy
7) cytokine therapy
bi-specific antibodies
- genetically enginerer antibodies that recognize tumor antigens and immune system cells
- one arm sees tumor and the other immune cell
immunoconjugates
antibodies coupled to a toxic substance
- bacterial toxins, chemotherapeutic drugs, radioisotopes
- must chose a tumor specific antigen. cross reactivity is a problem.
- conjugate must be endocytosed**
- F9ab’)2 fragments (no Fc reion) used to avoid non-specific binding
- basically antibodies armed with something to help them better to kill cells
- very portent
antibodies directed against growth factor receptors
- herceptin (tratuzumab) targets the Her2/Neu factor receptor which is overexpressed on 25% breast cancer
- bocks receptor/ligand interaction = decrease expression of Her2/Neu
- over expression of Her2/Neu correlates with a poor er prognosis
- quite effective
anti-id antibodies surface immunoglobulin of Bcell lymphomas
- cell lysis by ADCC or complement required to decrease tumor burden
- outgrowth of tumor cell mutants are a problem
- tends to reoccur
purging bone marrow of tumor cells
in bvitro purging of bone marrow tumor cells by anti-tumor antibody and complement could provide a tumor free source of bone marrow
-used with analogous bone marrow transplantation in B-cell lymphoma patients that have received chemotherapy and radiation